12:00 AM
 | 
Jul 30, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Delamanid: Phase I data

An open-label Phase I trial in healthy volunteers showed that no clinically relevant changes in delamanid exposure occurred when the compound was co-administered with HIV drugs Viread tenofovir or Kaletra lopinavir/ritonavir. Additionally, Viread had...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >